Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us    
Google
Web www.equitybulls.com
Union Budget
Budget 2011-2012 Home
Industry Expectations - Budget 2011-2012
Industry Reactions - Budget 2011-2012
Budget 2010-2011
Budget 2010-2011 Home
Industry Expectations - Budget 2010-2011
Industry Reactions - Budget 2010-2011
Contributor's Corner
Bonanza Portfolio
Hemant K Gupta
Krish Bhatt
S A A R T H I
Trinity Investments
Exchange Information
BSE 2009 Holidays
NSE 2009 Holidays
Investor Guide
Depository & Dematerialisation
Grievance Redressal
Investor Guide
SEBI
Trading of Securities
Transfer of Securities
Your Rights
Budget 2009-2010
Budget 2009-2010 Home
Industry Expectations - Budget 2009-2010
Industry Reactions - Budget 2009-2010
Interim Budget 2009-2010 Home
Industry Expectations - Interim Budget 2009
Budget 2008-2009
Railway Budget 2008-2009
Industry Expectations - Budget 2008
Union Budget 2008-2009
Highlights of Budget 2008-2009
Summary of Budget 2008-2009
Industry Reactions - Budget 2008
IPOs
Current IPOs
Past IPOs
IPO Subscription
Mutual Funds
Gold Exchange Traded Fund
MF Unique Holding
Forthcoming Dividends
ELSS Schemes Comparison
Tax Plans
New Fund Offers
Research
Arbitrages
Equity
Market Whispers
Tax Planning
Home
Equity Linked Savings Scheme
Post Office MIS
9% GOI Senior Citizens Savings Scheme
8% Savings (Taxable) Bonds
Kisan Vikas Patra
National Savings Certificate
Public Provident Fund
Research

| More

Crisil - Panacea Biotec Ltd - Independent Equity Research Report

Posted On: 2011-12-14 22:00:23

Panacea Biotec Ltd (Panacea) has so far witnessed strong business momentum in both combination vaccines and formulations. While demand continues to gain traction, Panacea's growth will likely hit a roadblock as WHO (World Health Organisation) has de-listed its combination vaccines, including the high-margin EasyFive, from the pre-qualified list of vaccines. We have lowered our FY12 estimates to account for the loss in business. However, we maintain our fundamental grade of 3/5 as we believe that the problem is likely to be a short term one and the long-term business prospects look optimistic. Growth momentum in combination vaccines stalled in the near term.

Combination vaccines had been witnessing strong traction in demand, apparent from EasyFive's ~220% y-o-y revenue growth in FY11. WHO has recently delisted the product because of quality management issues. Consequently, we expect growth to get stalled as UNICEF is the largest customer. However, management is expecting to fix the issue in 3-4 months. We expect the supplies to resume by Q1FY13 and remain optimistic on the long-term growth prospects of combination vaccines.

Expect gradual de-growth in polio vaccine sales

Polio vaccine sales declined by ~17% y-o-y in FY11 largely due to: 1) decline in procurement by UNICEF because of increase in polio eradication globally, and 2) Indian government now procuring vaccines on need basis only. However, we view limited near-term risk to demand for polio vaccines given the significant number of cases still recorded globally. Going ahead, we expect sales to de-grow, but on a more gradual curve.

New products and geographic expansion to benefit formulations

Formulation sales grew ~24% y-o-y in FY11, largely driven by strong traction in its existing products and entries into new markets. Exports grew by ~110% driven by strong demand for Tacrolimus and Cyclosporine in Latin America. Going ahead, we believe that catalysts such as expected approval in regulated markets and launch of new products will continue to crank the growth engine.

Revenue growth and profitability curve to cave-in in FY12

We expect FY12 revenue to decline ~25% y-o-y to ~Rs 8,650 mn and EBITDA margin to contract by 1,440 bps to ~8% on loss of EasyFive sales to UNICEF and higher raw material costs driven by unfavourable forex movement. We expect revenue and margins to improve to ~Rs 11,934 mn and 19.0% in FY13.

Valuations the current price has 'upside'

Based on our new estimates, we arrive at a fair value of Rs 100 per share. We propose a valuation grade of 4/5, indicating that the market price has upside from the current levels.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Disclaimer:The article above is a gist / extract of the original report prepared by the research firm / brokerage firm. This article is not to be considered as an offer to sell or a solicitation to buy any securities. This article is meant for general information only. www.equitybulls.com, its employees or owners or the research firms, its employees or owners won't be responsible for any liability that may arise from information, errors or omissions in these articles. www.equitybulls.com or its employees or owners / the research firms or its employees or clients or owners may from time to time hold positions in securities referred in this article. For detailed research reports, please contact the concerned research firm directly.





Other Headlines:

Nestle India - 4QCY16 Result Update - Better Times Awaited; Maintain REDUCE - Reliance Securities
Kalpataru Power Transmission - 3QFY17 Result Update - Growth Momentum Continues; Strong Order Book Offers High Revenue Visibility - Reliance Securities
NALCO - 3QFY17 Result Update - Strong Performance on Higher Volume, Realizations - Reliance Securities
Further Re-rating of HDFC Bank to come from Core earnings growth: Angel Broking
Cadila Healthcare - no 483 For Moraiya plant: Angel Broking
GlaxoSmithKline Consumer - 3QFY17 Result Update - Weak Demand Accentuated by Demonetization - Reliance Securities
MOIL - 3QFY17 Result Update - Stellar Performance to Continue; Upgrade to BUY - Reliance Securities
Techno Electric & Engineering - 3QFY17 Result Update - Strong Quarter; Order Pipeline Remains Robust - Reliance Securities
J. Kumar Infraprojects - 3QFY17 Result Update - Decent Performance on Execution Ramp-up - Reliance Securities
Views on Sun Pharmaceutical Industries Limited 3QFY2017 Results: Angel Broking
All the queries put to rest at Infosys Press Conference: Angel Broking
Hindustan Zinc - 3QFY17 Result Update - Higher Zinc Prices Aid Earnings, but Valuation Expensive; Reiterate REDUCE - Reliance Securities
Mangalam Cement - 3QFY17 Result Update - Robust Volume Growth Aids Performance - Reliance Securities
Power Grid Corporation - 3QFY17 Result Update - Higher Capitalization Continues to Drive Growth - Reliance Securities
HeidelbergCement - 3QFY17 Result Update - A Quiet Quarter; Expect Improvement Ahead - Reliance Securities
Bank of Baroda - 3QFY17 Result Update - Asset Quality Pressure Continues to Persist; Downgrade to HOLD - Reliance Securities
Steel Authority of India - 3QFY17 Result Update - Higher Raw Material Cost & Lower Volume Dent Margins - Reliance Securities
Hindalco - 3QFY17 Result Update - Strong Performance Continues; Valuation Pricey - Reliance Securities
KNR Constructions - 3QFY17 Result Update - Beats Estimates on Better Execution - Reliance Securities
Ahluwalia Contracts - 3QFY17 Result Update - Strong Performance on All Parameters - Reliance Securities
NBCC - 3QFY17 Result Update - Better Operating Performance; Prospect Remains Bright - Reliance Securities
Goodluck India - 3QFY17 Result Update - Subdued Quarter; Better Times Expected as Input Prices Stabilize - Reliance Securities
Alkem Laboratories - 3QFY2017 Result Update - Angel Broking
Bank Of Baroda - 3QFY2017 Result Update - Angel Broking
Garware Wall Ropes - 3QFY2017 Result Update - Angel Broking
Views on GlaxoSmithKline Pharmaceuticals Limited 3QFY2017 Results: Angel Broking
J.K. Cement - 3QFY17 Result Update - Healthy Operating Performance amid Dismal Volume Growth - Reliance Securities
Jubilant FoodWorks - 3QFY17 Result Update - Too Fast Too Soon; Downgrade to HOLD - Reliance Securities
Sonata Software - 3QFY17 Result Update - Unimpressive Show; IITS Revenue Disappoints - Reliance Securities
JK Lakshmi Cement - 3QFY17 Result Update - Better Operating Performance on Cost Savings - Reliance Securities
Dr. Reddy's Laboratories - 3QFY17 Result Update - Long-term Fundamentals Remain Intact; Headwinds to Persist in the Near-term - Reliance Securities
Titan Company - 3QFY17 Result Update - Dazzles in Dark Times - Reliance Securities
Union Bank of India - 3QFY17 Result Update - Asset Quality Pressure Persists; Downgrade to HOLD - Reliance Securities
Ramco Cements - 3QFY17 Result Update - Healthy Operating Performance Continues amid Realizations Pressure - Reliance Securities
Hexaware Technologies - 4QCY16 Result Update - Solid Quarter, Deal Wins Strong; Client-Specific Issue A Negative - Reliance Securities
eClerx Services - 3QFY17 Result Update - Disastrous Performance on All Counts - Reliance Securities
Punjab National Bank - 3QFY17 Result Update - Asset Quality Pressure Recedes; Reiterate HOLD - Reliance Securities
HeidelbergCement India: 3QFY17 Result: FIRST CUT - Reliance Securities
Views on Lupin Limited 3QFY2017 Results: Angel Broking
Skipper - 3QFY17 Result Update - Transmission Capex Play; On Right Track - Reliance Securities
NTPC - 3QFY17 Result Update - Improving Performance on Operational Metrics - Reliance Securities
Navkar Corporation - 3QFY17 Result Update - Stable Performance; Strong Volume Growth on the Cards - Reliance Securities
Views on IPCA Laboratories Ltd 3QFY2017 Results: Angel Broking
State Bank of India - 3QFY17 Result Update - Operating Performance Improves; Maintain BUY - Reliance Securities
MBL Infrastructures - 3QFY17 Result Update - Performance Back on Track; Concerns still Prevail - Reliance Securities
Crompton Greaves Consumer Electrical - 3QFY17 Result Update - Well-positioned to cash in the expected double-digit growth in light electrical industry - Reliance Securities
Views on ICICI Bank Ltd 3QFY2017 Results: Angel Broking
Views on Tech Mahindra Ltd 3QFY2017 Results: Angel Broking
Shree Cement - 3QFY17 Result Update - Power Division Mars Performance - Reliance Securities
Godrej Consumer - 3QFY17 Result Update - Commendable performance; but priced in - Reliance Securities


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2017